DRUG DISCOVERY SOLUTIONS

The Origins of Venomtech Limited

Venomtech's products are designed to help solve a significant and very common challenge in today's drug discovery: the failure to find good new drug candidates using conventional chemical libraries.

The company's Targeted Venom Discovery Arrays™ (TVDAs™) are the most comprehensive and flexible offers in the industry, coupled to an exclusive ready-to-use acoustic liquid delivery format that is rapidly becoming the standard worldwide. Venomtech is proud to help overcome significant barriers to the development of new, high value medicines.

Venomtech was founded in March 2010 by Steven Trim to help solve one of the problems he had often encountered as a pharmaceutical scientist - finding adequate new drug leads. Steve's passion and drive for drug discovery is intimately linked to his desire to advance human healthcare and to his personal experience of the challenges in drug discovery. During his tenure at Pfizer, he worked on several drug discovery programmes where the team struggled considerably to obtain good candidate molecules or adequate tools to rapidly advance its projects.

Venomtech Management Team

The management team comprises founder and full-time Managing Director Steven Trim, alongside Prof. Karol Sikora (Chairman), with Business Development Director Paul Grant, Commercialisation Director Paul Williamson and Ibrahim Sheikh Director of Finance.

Managing Director - Steven Trim

Steven Trim, Managing Director spent a decade working as a molecular biologist in drug discovery at Pfizer (Sandwich, Kent). He has worked extensively on pain therapeutics and developed expertise in tissue repair, gastrointestinal and respiratory fields. Having worked across molecular biology, pharmacology, biochemistry and anatomy, Steve has a deep understanding of drug discovery and the use of venoms and toxins in this area. Drawing on his experience at Pfizer, he founded Venomtech Ltd in 2010 with the goal of solving the problems the industry faces in finding new medicines.

Steve Trim - LinkedIn

Interim Chairman - Professor Karol Sikora

Professor Karol Sikora MA, MBBChir, PhD, MD, FRCR, FRCP, FRCPE, FFPM (Scientific Advisor) is a Consultant Oncologist at Hammersmith Hospital, London. He launched CancerPartnersUK, Britain's largest independent network of innovative cancer treatment centres. He was Chief of the World Health Organisation's Cancer Programme between 1997 and 1999 and has been an adviser to the UN's International Atomic Energy Agency. Karol provides invaluable expertise in oncology and therapeutics.

karolsikora.com

Business Development Director - Paul Grant​

Paul Grant  has been working in drug discovery business development for 10 years. He brings deep industry knowledge, contacts and scientific experience.

​His qualifications include an MSc and PhD (Neuroscience). 10+ years as a sales professional for Merck, DiscoveRx and Asterand. He has worked with major pharma, biotech, academic, CRO and diagnostic organisations across Europe.

Commercialisation Director – Paul Williamson

Paul Williamson (Commercialisation Director) has 20 years experience in high-tech business development. He has been working in entrepreneurial business development since 2001 leaving a senior sales position with GM and EDS to found start-up incubator Twoeyes Ventures in Australia and preparing over 70 companies for public and private investment. ​Taking a founding stake in a high-potential machinery client he grew and exited that business to found a medical simulation start-up with VC backing. Degree-qualified in Mechanical and Manufacturing Engineering and with further qualifications in Systems Engineering and an MBA.

Finance Director - Ibrahim Sheikh

Ibrahim Sheikh (Finance Director) has 29 years of experience in commercial finance having started his ACCA management accountancy career with Grindlays Bank and then successfully moving onto JP Morgan Chase, where he  was responsible for performance and budgetary reporting across EMEA operations. Ibrahim was also responsible for the introduction of new disruptive ICT technologies for JP Morgan Chase delivering improvements in MIS reporting and significant cost savings. Building on success in the City, Ibrahim set up his own management consultancy specialising in the rollout of disruptive technologies across the financial management sector. ​Ibrahim is a BAB and UKTI Accredited Management Consultant working closely with both SMEs and Enterprise organisations delivering business development to senior management at a national and international level.